IL6 and pneumonia: The subsequent T cell-mediated immune response can be augmented byimmune checkpoint inhibitors, resulting in enhanced local and systemic antiviral immunity.COVID-19-infected pneumonia patients typically have severe immune abnormalities and risk ofcytokine release syndrome (CRS), which result into a decrease in T cells and natural killer(NK) cells and an increase in interleukin 6 (IL-6), the CD4/CD8 ratio (CD: cluster ofdifferentiation), fever, tissue/organ dysfunction, and an abnormal coagulation function.39–41